Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | OGA | O60502 | 2/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915930 | 1.00 | SIGMAR1 (0.43) | SIGMAR1OGAAGTR2KCNH2GAA | |
| SCHEMBL1439745 | 0.88 | CHRM2 (0.43) | AGTR2 | |
| SCHEMBL28593949 | 0.88 | CHRM2 (0.43) | AGTR2 | |
| SCHEMBL19465331 | 0.88 | CHRM2 (0.43) | AGTR2 | |
| SCHEMBL29304443 | 0.81 | NPC1 (0.38) | AGTR2 | |
| SCHEMBL29940175 | 0.78 | CHRM2 (0.41) | — | |
| SCHEMBL1444237 | 0.78 | CHRM2 (0.41) | — | |
| SCHEMBL19408441 | 0.78 | CHRM2 (0.41) | — | |
| SCHEMBL18387515 | 0.78 | CHRM2 (0.41) | — | |
| SCHEMBL8833545 | 0.78 | CHRM2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | SIGMAR1 233/4885OGA 4050/4885AGTR2 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.